News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
183,376 Results
Type
Article (17593)
Company Profile (120)
Press Release (165663)
Section
Business (58511)
Career Advice (941)
Deals (9399)
Drug Delivery (36)
Drug Development (23512)
Employer Resources (70)
FDA (2396)
Job Trends (4269)
News (92738)
Policy (5844)
Tag
Academia (485)
Alliances (16300)
Alzheimer's disease (417)
Antibody-drug conjugate (ADC) (70)
Approvals (2361)
Artificial intelligence (88)
Bankruptcy (81)
Best Places to Work (2927)
Biotechnology (111)
Breast cancer (76)
Cancer (697)
Career advice (756)
CAR-T (80)
Cell therapy (232)
Clinical research (18567)
Collaboration (363)
Compensation (80)
COVID-19 (743)
C-suite (108)
Data (595)
Diabetes (55)
Diagnostics (1075)
Drug discovery (54)
Earnings (15818)
Employer resources (68)
Events (31254)
Executive appointments (313)
FDA (2641)
Funding (307)
Gene therapy (156)
GLP-1 (257)
Government (624)
Healthcare (2427)
Immunology and inflammation (53)
Infectious disease (792)
Inflammatory bowel disease (64)
Interviews (137)
IPO (4121)
Job creations (1476)
Job search strategy (701)
Layoffs (158)
Legal (1190)
Lung cancer (82)
Manufacturing (124)
Medical device (771)
Medtech (772)
Mergers & acquisitions (5445)
Metabolic disorders (200)
Neuroscience (604)
NextGen: Class of 2025 (1457)
Non-profit (475)
Northern California (767)
Obesity (112)
Opinion (171)
Patents (60)
People (22094)
Phase I (7208)
Phase II (8858)
Phase III (4996)
Pipeline (323)
Postmarket research (312)
Preclinical (2922)
Press Release (61)
Radiopharmaceuticals (81)
Rare diseases (154)
Real estate (2450)
Regulatory (4509)
Research institute (516)
Resumes & cover letters (152)
Series A (74)
Southern California (716)
Startups (1785)
United States (6419)
Vaccines (207)
Weight loss (80)
Date
Last 7 days (218)
Last 30 days (932)
Last 365 days (12542)
2025 (1714)
2024 (12719)
2023 (13269)
2022 (16165)
2021 (17027)
2020 (13312)
2019 (9589)
2018 (7626)
2017 (9040)
2016 (8174)
2015 (9480)
2014 (9802)
2013 (9515)
2012 (6147)
2011 (6492)
2010 (5869)
Location
Africa (330)
Asia (13528)
Australia (2771)
California (1802)
Canada (637)
China (163)
Connecticut (74)
Europe (30194)
Florida (194)
Illinois (121)
Indiana (96)
Maryland (275)
Massachusetts (1417)
Michigan (70)
Minnesota (105)
New Jersey (481)
New York (456)
North Carolina (320)
Northern California (767)
Ohio (51)
Pennsylvania (384)
South America (403)
Southern California (716)
Texas (208)
Washington State (300)
183,376 Results for "viva biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
On March 28, 2024, Viva Biotech Holdings Group announced that the Group’s revenue during the Reporting Period achieved RMB2,155.6 million; and our gross profit amounted to RMB738.5 million.
March 28, 2024
·
17 min read
Viva Biotech Secures Approximately US$ 210 Million Funding
On November 20, 2023 , Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US$210 million and bringing in the strategic investors, Temasek, Highlight Capital (HLC), and True Light.
November 20, 2023
·
3 min read
Executive appointments
Women Leaders Decline in Biotech’s Era of ‘Proven Leadership’
Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a
BioSpace
analysis. This is happening in an era of biotech where new company founders are searching for CEOs with a track record.
February 5, 2025
·
8 min read
·
Annalee Armstrong
Business
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
August 29, 2024
·
17 min read
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
On June 11, 2023, Viva Biotech Holdings Group announced that Viva Shanghai, the primary entity for Viva Biotech’s CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.
June 16, 2023
·
4 min read
Legal
Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug
Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.
February 18, 2025
·
1 min read
·
Annalee Armstrong
Cystic Fibrosis
Cystic Fibrosis Biotech Sionna Announces $150M IPO
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space dominated by Vertex.
February 3, 2025
·
1 min read
·
Dan Samorodnitsky
Latest Updates of Viva Biotech’s Portfolio Companies
Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies’ long-term development.
March 6, 2024
·
9 min read
Leadership
Biotech CEO Sisterhood Fills ‘Unmet Need’ for Fellowship Among Women Leaders
At the J.P. Morgan Healthcare Conference, the Biotech CEO Sisterhood assembled in Union Square to showcase the large group of women and allies in biopharma as their authentic selves.
February 5, 2025
·
4 min read
·
Annalee Armstrong
Business
Viva Biotech’s Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
July 20, 2023
·
3 min read
1 of 18,338
Next
